A Pilot Study for Collection of Anti-Influenza A Immune Plasma
- Conditions
- Influenza A Virus InfectionSwine Flu
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2019-08-19
- Target Recruit Count
- 102
- Registration Number
- NCT00984451
- Locations
- 🇺🇸
AIDS Clinical Trials Unit, NYU School of Medicine, New York, New York, United States
🇺🇸Cornell Clinical Trials Unit, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2015-03-18
- Target Recruit Count
- 567
- Registration Number
- NCT00980148
- Locations
- 🇺🇸
University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸Los Angeles County Department of Public Health - Sexually Transmitted Disease Program, Los Angeles, California, United States
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
- Conditions
- H1N1 Influenza Virus
- Interventions
- Biological: H1N1 vaccine high doseBiological: H1N1 vaccine low dose
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2012-08-10
- Target Recruit Count
- 390
- Registration Number
- NCT00978120
- Locations
- 🇺🇸
University of Pittsburgh Asthma Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Phase I STEBVax in Healthy Adults
- Conditions
- Toxic Shock Syndrome Staphylococcal
- Interventions
- Biological: STEBVax vaccine
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2015-06-19
- Target Recruit Count
- 29
- Registration Number
- NCT00974935
- Locations
- 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States
VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old
- Conditions
- Novel Swine-OriginInfluenza A Virus, H1N1 Subtype
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 20
- Registration Number
- NCT00973895
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- Conditions
- InfectionsMyelokathexisNeutropeniaLeukopeniaWarts
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT00967785
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
- Conditions
- Influenza
- Interventions
- Biological: AS03Biological: Inactivated H1N1 Vaccine
Inducing Remission in Type 1 Diabetes With Alefacept
- Conditions
- New-onset Type 1 Diabetes Mellitus
- Interventions
- Biological: AlefaceptDrug: Placebo
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2017-07-06
- Target Recruit Count
- 49
- Registration Number
- NCT00965458
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
H1N1 Vaccine in Pregnant Women
- Conditions
- Influenza
- Interventions
- Biological: Inactivated H1N1 Vaccine
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2012-12-03
- Target Recruit Count
- 120
- Registration Number
- NCT00963430
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Saint Louis University - Center for Vaccine Development, St. Louis, Missouri, United States
🇺🇸Baylor College of Medicine - Department of Molecular Virology and Microbiology, Houston, Texas, United States
Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2014-12-24
- Target Recruit Count
- 789
- Registration Number
- NCT00963157
- Locations
- 🇺🇸
Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Stanford, California, United States
🇺🇸University of Iowa - Vaccine Research & Education Unit, Iowa City, Iowa, United States
🇺🇸Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States